828 related articles for article (PubMed ID: 11893235)
1. Botulinum toxin B: a review of its therapeutic potential in the management of cervical dystonia.
Figgitt DP; Noble S
Drugs; 2002; 62(4):705-22. PubMed ID: 11893235
[TBL] [Abstract][Full Text] [Related]
2. Botulinum toxin type B for cervical dystonia.
Costa J; Espírito-Santo C; Borges A; Ferreira JJ; Coelho M; Moore P; Sampaio C
Cochrane Database Syst Rev; 2005 Jan; (1):CD004315. PubMed ID: 15674941
[TBL] [Abstract][Full Text] [Related]
3. Botulinum toxin type B for cervical dystonia.
Marques RE; Duarte GS; Rodrigues FB; Castelão M; Ferreira J; Sampaio C; Moore AP; Costa J
Cochrane Database Syst Rev; 2016 May; 2016(5):CD004315. PubMed ID: 27176573
[TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin type A therapy for cervical dystonia.
Castelão M; Marques RE; Duarte GS; Rodrigues FB; Ferreira J; Sampaio C; Moore AP; Costa J
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD003633. PubMed ID: 29230798
[TBL] [Abstract][Full Text] [Related]
5. Botulinum toxin type A therapy for cervical dystonia.
Rodrigues FB; Duarte GS; Marques RE; Castelão M; Ferreira J; Sampaio C; Moore AP; Costa J
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD003633. PubMed ID: 33180963
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.
Brashear A; Lew MF; Dykstra DD; Comella CL; Factor SA; Rodnitzky RL; Trosch R; Singer C; Brin MF; Murray JJ; Wallace JD; Willmer-Hulme A; Koller M
Neurology; 1999 Oct; 53(7):1439-46. PubMed ID: 10534248
[TBL] [Abstract][Full Text] [Related]
7. Botulinum toxin type A versus botulinum toxin type B for cervical dystonia.
Duarte GS; Castelão M; Rodrigues FB; Marques RE; Ferreira J; Sampaio C; Moore AP; Costa J
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD004314. PubMed ID: 27782297
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.
Brin MF; Lew MF; Adler CH; Comella CL; Factor SA; Jankovic J; O'Brien C; Murray JJ; Wallace JD; Willmer-Hulme A; Koller M
Neurology; 1999 Oct; 53(7):1431-8. PubMed ID: 10534247
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized-controlled trial.
Poewe W; Burbaud P; Castelnovo G; Jost WH; Ceballos-Baumann AO; Banach M; Potulska-Chromik A; Ferreira JJ; Bihari K; Ehler E; Bares M; Dzyak LA; Belova AN; Pham E; Liu WJ; Picaut P
Mov Disord; 2016 Nov; 31(11):1649-1657. PubMed ID: 27653448
[TBL] [Abstract][Full Text] [Related]
10. BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study).
Truong DD; Cullis PA; O'Brien CF; Koller M; Villegas TP; Wallace JD
Mov Disord; 1997 Sep; 12(5):772-5. PubMed ID: 9380065
[TBL] [Abstract][Full Text] [Related]
11. The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials.
Lew MF; Brashear A; Factor S
Neurology; 2000; 55(12 Suppl 5):S29-35. PubMed ID: 11188982
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.
Pappert EJ; Germanson T;
Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274
[TBL] [Abstract][Full Text] [Related]
13. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia.
Lew MF; Adornato BT; Duane DD; Dykstra DD; Factor SA; Massey JM; Brin MF; Jankovic J; Rodnitzky RL; Singer C; Swenson MR; Tarsy D; Murray JJ; Koller M; Wallace JD
Neurology; 1997 Sep; 49(3):701-7. PubMed ID: 9305326
[TBL] [Abstract][Full Text] [Related]
14. Botulinum toxin type A versus botulinum toxin type B for cervical dystonia.
Costa J; Borges A; Espírito-Santo C; Ferreira J; Coelho M; Moore P; Sampaio C
Cochrane Database Syst Rev; 2005 Jan; (1):CD004314. PubMed ID: 15674940
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia: ASPEN-1 Phase 3 Randomized Controlled Trial.
Comella CL; Jankovic J; Hauser RA; Patel AT; Banach MD; Ehler E; Vitarella D; Rubio RG; Gross TM;
Neurology; 2024 Feb; 102(4):e208091. PubMed ID: 38295339
[TBL] [Abstract][Full Text] [Related]
16. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
[TBL] [Abstract][Full Text] [Related]
17. Botulinum toxin type A versus anticholinergics for cervical dystonia.
Rodrigues FB; Duarte GS; Castelão M; Marques RE; Ferreira J; Sampaio C; Moore AP; Costa J
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD004312. PubMed ID: 33852744
[TBL] [Abstract][Full Text] [Related]
18. A mixed treatment comparison to compare the efficacy and safety of botulinum toxin treatments for cervical dystonia.
Han Y; Stevens AL; Dashtipour K; Hauser RA; Mari Z
J Neurol; 2016 Apr; 263(4):772-80. PubMed ID: 26914922
[TBL] [Abstract][Full Text] [Related]
19. [A double-blind comparative study to evaluate the efficacy and safety of NerBloc® (rimabotulinumtoxinB) administered in a single dose to patients with cervical dystonia].
Kaji R; Shimizu H; Takase T; Osawa M; Yanagisawa N
Brain Nerve; 2013 Feb; 65(2):203-11. PubMed ID: 23399677
[TBL] [Abstract][Full Text] [Related]
20. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.
Chapman MA; Barron R; Tanis DC; Gill CE; Charles PD
Clin Ther; 2007 Jul; 29(7):1325-37. PubMed ID: 17825685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
